ArticleThe Journal of clinical investigation2007
Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis.
Article in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 156 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
156 citing papers in PubMed.
- Organelle interplay in host responses and mycobacterial resilience.EMBO reports · 2026Review
- Mitochondrial STAT3-mediated suppression of apoptosis constrains antimycobacterial immunity.bioRxiv : the preprint server for biology · 2026Article
- Construction and characterization of novelInfection and immunity · 2026Article
- Cell death pathways in response toInfection and immunity · 2025Review
- Live Attenuated Vaccines against Tuberculosis: Targeting the Disruption of Genes Encoding the Secretory Proteins of Mycobacteria.Vaccines · 2024Review
- Article
- Virulence Factors ofPathogens (Basel, Switzerland) · 2023Review
- Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination.Journal of cellular immunology · 2023Article
- Fighting Tuberculosis: In Search of a BCG Replacement.Microorganisms · 2022Review
- Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles.International journal of pharmaceutics · 2022Article
- Early alveolar macrophage response and IL-1R-dependent T cell priming determine transmissibility of Mycobacterium tuberculosis strains.Nature communications · 2022Article
- Mycobacterial acyl carrier protein suppresses TFEB activation and upregulates miR-155 to inhibit host defense.Frontiers in immunology · 2022Article
- Pathological and protective roles of dendritic cells inFrontiers in cellular and infection microbiology · 2022Review
- The Role of NRF2 in Mycobacterial Infection.Antioxidants (Basel, Switzerland) · 2021Review
- Platelet Activation and the Immune Response to Tuberculosis.Frontiers in immunology · 2021Review
- Article
- Immunometabolism during Mycobacterium tuberculosis Infection.Trends in microbiology · 2020Review
- Towards new TB vaccines.Seminars in immunopathology · 2020Review
- Article
- Targeting Autophagy as a Strategy for Developing New Vaccines and Host-Directed Therapeutics Against Mycobacteria.Frontiers in microbiology · 2020Review
96 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
The inhibition of apoptosis of infected host cells is a well-known but poorly understood function of pathogenic mycobacteria. We show that inactivation of the secA2 gene in Mycobacterium tuberculosis, which encodes a component of a virulence-associated protein secretion system, enhanced the apoptosis of infected macrophages by diminishing secretion of mycobacterial superoxide dismutase. Deletion of secA2 markedly increased priming of antigen-specific CD8(+) T cells in vivo, and vaccination of mice and guinea pigs with a secA2 mutant significantly increased resistance to M. tuberculosis challenge compared with standard M. bovis bacille Calmette-Guérin vaccination. Our results define a mechanism for a key immune evasion strategy of M. tuberculosis and provide what we believe to be a novel approach for improving mycobacterial vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.